For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Novo Nordisk A/S (NVO) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-27): Designation Watch · Gem Score +12 (−100…+100 Quality+Value blend) · Quality 56 · Value -17 · Sentiment -42 (timing only, not weighted) · Composite fair value $48.24 vs $47.11 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Novo Nordisk A/S
NVO NYSENovo Nordisk A/S Sponsored ADR is a global healthcare company focused on discovering, developing, manufacturing, and marketing pharmaceutical products. Novo Nordisk A/S Sponsored ADR serves patients and healthcare providers through two main business segments: Diabetes and Obesity Care, which includes therapies for diabetes, obesity, cardiovascular, and related emerging treatment areas, and Rare Disease, which addresses specialized conditions such as rare blood disorders and endocrine disorders. The company offers a broad portfolio of prescription medicines and treatment solutions used in chronic disease management across major international markets. Novo Nordisk A/S Sponsored ADR plays a significant role in the pharmaceutical industry by providing products that support long-term treatment needs in both primary care and specialty care settings.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
Novo Nordisk A/S is a foreign private issuer — it reports to the U.S. SEC once a year (on Form 20-F or 40-F) rather than filing the quarterly statements (10-Q) that U.S.-domiciled companies must submit. Our financial statements are read directly from SEC filings, so for this company only annual figures exist at the source.
This is a property of how the company files, not missing or broken data — its filing history shows 5 annual reports, the latest filed 2026-02-04, and no quarterly filings . The company may still publish quarterly results on its own investor-relations site.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 3.59
Total Equity: $30.27B
Shares: 4,447,700,000
Total Debt: $20.43B
Cash: $4.13B
EBITDA: $22.20B
Total Debt: $20.43B
Cash: $4.13B
Revenue: $48.22B
Revenue: $48.22B
Revenue: $48.22B
Total Equity: $30.27B
Tax Rate: 21.5%
Equity: $30.27B
Total Debt: $20.43B
Cash: $4.13B
Current Liabilities: $33.65B
Long-Term Debt: $18.56B
Total Debt: $20.43B
Total Equity: $30.27B
Shares: 4,447,700,000
Shares: 4,447,700,000
CapEx: -$9.38B
Shares: 4,447,700,000
Stock Price: $46.76
Net Income: $15.98B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 24, 2026 2:43pm (44d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $22.0B | $27.6B | $36.2B | $45.3B | $48.2B |
| Cost of Revenue | $3.7B | $4.4B | $5.6B | $6.9B | $9.2B |
| Gross Profit | $18.3B | $23.2B | $30.7B | $38.4B | $39.0B |
| Operating Expenses | $9.1B | $11.5B | $14.7B | $18.3B | $19.1B |
| Operating Income | $9.1B | $11.7B | $16.0B | $20.0B | $19.9B |
| Net Income | $7.5B | $8.7B | $13.1B | $15.8B | $16.0B |
| EBITDA | — | $12.7B | $17.1B | $21.4B | $22.2B |
| EPS | $3.24 | $3.82 | $2.91 | $3.54 | $3.60 |
| EPS (Diluted) | $3.24 | $3.81 | $2.90 | $3.53 | $3.59 |
Balance Sheet (Annual)
Last updated: Aug 24, 2026 2:43pm (44d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.7B | $2.0B | $2.2B | $2.4B | $4.1B |
| Total Current Assets | $13.4B | $16.9B | $21.8B | $25.1B | $26.9B |
| Total Assets | $30.3B | $37.6B | $49.1B | $72.7B | $84.7B |
| Current Liabilities | $15.5B | $18.9B | $26.5B | $33.9B | $33.6B |
| Long-Term Debt | $2.0B | $3.8B | $3.2B | $14.0B | $18.6B |
| Total Liabilities | $19.3B | $24.6B | $32.4B | $50.3B | $54.4B |
| Total Equity | $11.0B | $13.0B | $16.6B | $22.4B | $30.3B |
| Retained Earnings | $11.2B | $12.6B | $16.4B | $22.5B | $30.5B |
Cash Flow (Annual)
Last updated: Aug 24, 2026 2:43pm (44d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $8.6B | $12.3B | $17.0B | $18.9B | $18.6B |
| Capital Expenditure | -$988.3M | -$1.9B | -$4.0B | -$7.4B | -$9.4B |
| Free Cash Flow | $7.6B | $10.4B | $13.0B | $11.5B | $9.2B |
| Acquisitions (net) | -$2.9B | -$1.1B | $0 | -$12.8B | $0 |
| Net Debt Issued / (Repaid) | $2.4B | -$375.7M | -$228.9M | $11.4B | $3.9B |
| Dividends Paid | -$3.4B | -$3.9B | -$5.0B | -$6.9B | -$8.1B |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | -$327.3M | $338.9M | $289.9M | $126.1M | $1.8B |
Growth Trends (YoY %)
Last updated: Aug 24, 2026 2:43pm (44d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +25.7% | +31.3% | +25.0% | +6.4% |
| Gross Profit Growth | +26.8% | +32.3% | +25.1% | +1.8% |
| Operating Income Growth | +27.6% | +37.1% | +25.1% | -0.5% |
| Net Income Growth | +16.3% | +50.7% | +20.7% | +1.4% |
| EBITDA Growth | — | +35.0% | +24.6% | +4.0% |
Dividend History (Last 20)
Last updated: Aug 19, 2026 8:02pm (49d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-08-17 | $0.58 | — | — | — |
| 2026-03-30 | $1.28 | — | — | — |
| 2025-08-18 | $0.58 | — | — | — |
| 2025-03-31 | $1.10 | — | — | — |
| 2024-08-16 | $0.51 | — | — | — |
| 2024-03-22 | $0.93 | — | — | — |
| 2023-08-18 | $0.22 | — | — | — |
| 2023-03-24 | $0.59 | — | — | — |
| 2022-08-12 | $0.29 | — | — | — |
| 2022-03-25 | $0.51 | — | — | — |
| 2021-08-16 | $0.28 | — | — | — |
| 2021-03-26 | $0.46 | — | — | — |
| 2020-08-14 | $0.26 | — | — | — |
| 2020-03-27 | $0.39 | — | — | — |
| 2019-08-16 | $0.22 | — | — | — |
| 2019-03-22 | $0.39 | — | — | — |
| 2018-08-17 | $0.23 | — | — | — |
| 2018-03-23 | $0.40 | — | — | — |
| 2017-08-17 | $0.17 | — | — | — |
| 2017-03-23 | $0.24 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-08-27 02:39Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-26 15:48The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The raw trajectory tells a clear deceleration story that the models are underweighting. Revenue went $21.9B → $27.6B → $36.2B → $45.3B → $48.2B — that's 26%, 31%, 25%, then 6.4%. Net income growth collapsed from ~50% YoY in 2022-2023 to 1.4% in 2025. Operating income actually declined ($20.0B → $19.9B) despite $2.9B of incremental revenue, meaning incremental operating margin was negative on the last $2.9B. That is not a "mature earner" gliding — that's a franchise hitting a wall on price, mix, or manufacturing cost simultaneous with LLY taking share. The pre-flight tag of "high-growth" is stale; the rule-based "mature earner" is closer to right, but even that undersells the inflection: this is a formerly-hyper-growth compounder decelerating fast enough that the P/E compression from ~40x to 13x is arguably rational, not an anomaly.
The synthesis verdict of "+8.4% upside to $51" and the narrative layer's "7.8% discount to DCF" are doing suspicious work with the FCF line. FCF CAGR is -15.8% and 2025 capex was $9.37B against $18.56B OCF — free cash conversion is roughly 50% of net income ($9.19B FCF vs $15.96B NI), and capex is running at ~19% of revenue for a pharma. That's the manufacturing buildout for GLP-1 supply, but it also means the "13x P/E, cheap!" framing masks a ~23x P/FCF that is not cheap for a company growing revenue 6% and earnings 1%. Current ratio of 0.80 and $20.4B debt against $4.1B cash isn't dangerous at this cash generation, but it removes the balance-sheet-optionality argument for aggressive M&A that some bulls lean on. ROE of 53% and ROIC of 34% are still elite — those are the numbers that justify holding, not the growth.
The contrarian case the models flirt with but don't commit to: LLY's tirzepatide (and now retatrutide) is clinically superior on weight loss endpoints, and once you're behind on efficacy in an indication where efficacy is the whole game, share loss compounds because formulary decisions, physician defaults, and patient switching all lag but don't reverse. Novo's response — CagriSema — disappointed in Phase 3 last December (weight loss ~22% vs the 25%+ target), which is exactly why the stock is at $47 down from $148. The market forces model's "losing a winner-take-most battle" read is the one to take seriously; the narrative layer's "steady compounder, moderate durability" is too generous. If GLP-1 pricing compresses 15-20% as Medicare negotiation and competition bite in 2026-2027 while volume growth slows to single digits, 2027 EPS could be flat to down from 2025, and 13x on flat earnings isn't cheap — it's fair-to-rich.
Where I land: the synthesis "slight upside to $51" is directionally plausible but built on a DCF that likely uses too-generous terminal growth and understates capex intensity. The thesis evaluation's near-zero score (-1) is honest — bull and bear masses genuinely offset. My read: fair value is $45-52 depending on whether you believe operating margin stabilizes at 41% or drifts to 35-37% as LLY pressure and manufacturing deleverage bite. At $47.80 you're paying roughly fair for a decelerating franchise with real competitive erosion, offset by a 3.9% yield, a still-elite ROIC, and non-zero pipeline optionality (oral semaglutide, amycretin). That's not a buy, it's a hold-if-you-own-it. The one scenario that flips me bullish is amycretin Phase 2 data reading out competitively vs retatrutide in 2026 — until then, LLY at 30x with better data is a better risk/reward than NVO at 13x with worse data, even accounting for the multiple gap. I dissent mildly from the "slight upside" verdict: the composite is anchored on trailing earnings that won't repeat cleanly, and the -15.8% FCF CAGR is a bigger flag than the models weight.
GPT Reading
Novo Nordisk’s raw numbers say “excellent business, no longer excellent trajectory.” The five-year build is remarkable: revenue rose from $21.94B in 2021 to $48.16B in 2025, while net income more than doubled from $7.44B to $15.96B. Even after that surge, profitability remains elite, with 80.98% gross margin, 41.3% operating margin, 33.1% net margin, 52.8% ROE, and 33.6% ROIC. On those metrics alone, 13.1x earnings and 10.2x EV/EBITDA look cheap for a franchise that still prints nearly $19B of operating cash flow. But the key change is that growth has clearly fallen off the boil: 2025 revenue grew only 6.4% and earnings only 1.4%, versus the much stronger multi-year CAGR. That deceleration matters more than the backward-looking quality metrics. This is not being valued like a hyper-growth GLP-1 platform anymore; it is being valued like a dominant pharma franchise whose best surprise years may already be in the base.
What stands out most is the margin pattern. Revenue increased from $45.25B in 2024 to $48.16B in 2025, yet operating income actually slipped from $20.00B to $19.89B. Gross profit rose only modestly from $38.32B to $39.00B, meaning gross margin compressed from roughly 84.7% to 81.0%. Net income still edged up to $15.96B from $15.74B, but that was not driven by stronger operating leverage. For a company whose valuation once depended on the idea that scale in obesity and diabetes would widen the moat and expand margins, flat-to-down operating profit on higher sales is a warning flag. The cash flow statement tells a similar story: operating cash flow was a huge $18.56B, but free cash flow was only $9.19B because capex was a massive $9.37B. That capex may be rational if it relieves supply constraints and extends growth, but for now it means investors are not actually receiving the full benefit of the income statement in cash.
The market is therefore not obviously mispricing Novo by slapping a low multiple on a pristine asset; it is discounting a business that may be entering a more capital-intensive, more competitive phase. At a $215.18B market cap, investors are paying about 4.35x sales and roughly 13x earnings for a company with world-class economics but suddenly mature-looking near-term growth. That feels close to fair, not obviously cheap. If 2025 is the new run-rate—mid-single-digit revenue growth, flat operating income, and heavy reinvestment—then the stock does not deserve a premium growth multiple. The low current ratio of 0.80 is not alarming for this kind of cash generator, and debt of $20.41B against $30.24B of equity is manageable, but neither balance sheet nor valuation creates a strong enough backstop to ignore the possibility that Novo is transitioning from scarcity-driven GLP-1 demand euphoria into normal pharma competition and reimbursement friction. My read is that the stock deserves to trade where it is until it proves the 2025 slowdown is temporary.
The best case against this skepticism is straightforward and serious: you are still buying one of the best businesses in global pharma at a multiple usually reserved for slower, less profitable peers. A 33% net margin and 18.9% ROA are extraordinary. Even after capex, $9.19B of free cash flow supports a near-4% dividend yield with only a 50.5% payout ratio. If the 2025 capex surge is principally buildout for obesity manufacturing, then today’s depressed free cash flow could be the setup for tomorrow’s acceleration. Likewise, a 6.4% revenue increase on a $45B base is still meaningful in absolute dollars, and the 2025 operating-income slippage was tiny—$19.89B versus $20.00B—hardly evidence of franchise deterioration on its own. A bull would say the market is anchoring too hard on one year of digestion after an extraordinary ramp, and that any reacceleration would make 13x earnings look plainly wrong.
I weigh that counterargument differently because the burden of proof has shifted. Novo no longer needs to show it has a great business; that is obvious. It needs to show that growth and margins can coexist again after the land-grab phase. What would change my mind is specific: if the next annual print showed revenue back above 10-12% growth with operating income growing at least in line with sales, I would become materially more constructive, especially if capex normalizes and free cash flow rebounds toward $12B-$14B. Conversely, another year like 2025—revenue up mid-single digits, operating profit flat or down, free cash flow held back by ongoing heavy investment—would make even 13x earnings look less like a bargain and more like the correct multiple for a peak-ish franchise.
Grok Reading
The numbers tell a story of a franchise hitting the wall in real time. Novo Nordisk grew revenue from $21.9B in 2021 to $48.2B in 2025, a multi-year GLP-1 compound that produced 33% net margins and a 53% ROE, but the slope has collapsed: recent revenue is up only 6.4% year-over-year and net income barely budged, $15.74B to $15.96B. Operating income actually slipped from $20.00B to $19.89B despite the top-line gain, so incremental dollars are no longer dropping through at the historical rate. Free cash flow of $9.19B against $18.56B of operating cash flow and $9.37B of capex is the clearest tell—management is pouring nearly a full year of FCF into capacity just as volume growth decelerates, and the trailing FCF CAGR of -15.8% is not a rounding error. At $47.80 the stock screens at 13.1x earnings, 4.4x sales, and 10.2x EV/EBITDA with a 3.9% dividend yield; those multiples are mature-pharma territory, not high-growth, and the rule-based “mature earner” label fits the 2025 income statement far better than the residual “high-growth” narrative still floating around the category.
What stands out against the models is the contradiction between still-elite profitability and the sudden loss of operating leverage. Gross margin remains 81% and net margin 33%, ROIC is 34%, and the balance sheet carries $20.4B of debt against only $4.1B of cash with a current ratio of 0.80—tight liquidity for a company mid-buildout. The market is not ignoring this: the pre-flight thesis correctly notes the discount to Eli Lilly’s multiple, and the market-forces layer’s “losing a winner-take-most battle” framing is visible in the flat operating line. Thesis evaluation is essentially a coin flip (-1 score), and the valuation composite’s $51 signal-adjusted fair value is only ~7% above the print. The story the numbers tell is not “obesity optionality undervalued”; it is “growth has normalized, margins are under pressure, and the market has already marked the stock as a mid-single-digit compounder with a competitive share question.”
The strongest case against this read is that 13x earnings and a 4% yield on a franchise that still prints $16B of net income with 80%+ gross margins is simply too cheap if the obesity TAM keeps expanding and capex converts into volume. A smart opponent would cite the five-year revenue ramp, the still-positive 15% revenue CAGR, pipeline optionality that is invisible in trailing multiples, and the fact that FCF compression is intentional manufacturing investment rather than structural decay. They would also note that a 50% payout ratio leaves room to keep the dividend growing even if earnings stall near-term. I weigh that less heavily because the 2025 inflection—operating income down, earnings +1.4%, FCF half of NI—is already evidence that scale advantages are being contested, and Eli Lilly’s clinical and commercial momentum is a real share-shift risk rather than noise. The multiple discount to LLY exists for a reason; treating it as pure mispricing requires assuming Novo holds share and pricing power that the latest P&L no longer fully supports.
What would flip the verdict is a re-acceleration of revenue growth back above 12–15% with operating margin stabilizing at or above 41%, or clear evidence that Wegovy/Ozempic volumes are taking share again rather than ceding it—specifically next two quarters of sequential prescription trends and any update that FCF recovers above $12B as capex intensity rolls off. A sustained drop in net margin below 28% or another year of sub-5% revenue growth with flat-to-down EBIT would confirm the bear case and push the stock toward overvalued at this price.
Qwen Reading local experiment · off-panel
The number that should stop you cold is not the 13.1x P/E or the 4.35x P/S — it's the operating income line. Revenue grew 6.4% from $45.25B to $48.16B, yet operating income *fell* from $20.00B to $19.89B. Gross margin compressed roughly 370 basis points (84.7% to 81.0%), and operating margin dropped from 44.2% to 41.3%. Net income crept up 1.4% to $15.96B, which means the company is buying that incremental revenue at a margin cost that is eating the entire top-line gain. This is not a company in a temporary supply pinch; this is a company whose incremental dollar of GLP-1 revenue is worth materially less than the dollar it earned two years ago. The rule-based model slaps "mature_earner" on this with 0.95 confidence, and the pre-flight layer calls it "high-growth." The data resolves that contradiction in favor of the former: a 6.4% revenue growth rate and 1.4% earnings growth rate is not high-growth. It is a company that has already had its growth inflection and is now in the expensive part of the cycle.
What makes the FCF story genuinely uncomfortable is the capex line. $9.37B of capex against $18.56B of operating cash flow leaves $9.19B of free cash flow, and the FCF CAGR is *negative* at -15.8%. Novo is spending nearly 20% of revenue on capital expenditure — a level more typical of a semiconductor fab or a chemical plant than a pharmaceutical company — and the revenue it is buying with that spend is growing at 6%. The current ratio of 0.80, below 1.0, is a working-capital warning that the market is underweighting: this is a company with $20.41B of debt, only $4.12B of cash, and a balance sheet that is getting tighter even as it builds out manufacturing. ROIC of 33.6% and ROE of 52.8% are still elite, but those are trailing numbers built on the 2021-2023 growth wave. The forward ROIC on the $9.37B of new capacity, if it earns the same 6% growth rate, is going to look a lot less impressive.
The prior models' "slight_upside" verdict with a signal-adjusted fair value of $51.07 against a $47.80 price embeds roughly 7% upside, and I think that is the right order of magnitude but for the wrong reasons. The valuation synthesis treats the 13x P/E as a discount to Eli Lilly's 40x+ and calls it a mispricing. I disagree with that framing. Lilly is growing faster, has a clinically differentiated triple-agonist in Zepbound, and is not yet carrying the same capex burden. The 27x P/E gap is not a market error; it is a growth-rate and competitive-position gap that the data supports. At 13x, the market is pricing Novo as a 6-8% grower with modest margin headroom, which is exactly what the 2025 income statement shows. You are not buying a discount; you are buying the number the company is actually producing.
The strongest case against my read is the pipeline and the obesity TAM. Semaglutide is not the only GLP-1, and Novo's oral formulations, next-gen incretins, and the broader rare-disease franchise (hemophilia, endocrinology) represent real optionality that a 13x multiple does not credit. A smart bull would point out that the $9.37B capex is building capacity for a category where global obesity prevalence is still climbing, that the 6.4% growth rate is a supply-constrained number rather than a demand-constrained one, and that 33% net margins with 53% ROE at 13x is still cheaper than most large-cap pharma on a risk-adjusted basis. I weigh this differently because the data does not yet show the demand side catching up: if the capex were converting into 20%+ revenue growth in 2026, the FCF story would flip and the 13x would be a genuine entry point. But the 2025 print shows the opposite — more capex, less growth, thinner margins. The pipeline is real but it is 2027-2028 revenue, and the market is not obligated to pay for it at today's price.
What would change my mind in either direction is specific and near-term. If Q1 2026 revenue growth reaccelerates above 15% year-over-year while gross margin stabilizes above 82%, that would confirm the 2025 deceleration was a supply artifact and the 13x P/E becomes a genuine mispricing I would upgrade to undervalued. Conversely, if Eli Lilly's next Zepbound head-to-head data shows a clinically meaningful superiority in weight-loss efficacy or tolerability, and Novo's 2026 guidance implies sub-5% growth, the 13x P/E is not a floor — it is the starting point of a de-rating toward 10-11x, which would put the stock in the low $30s. The capex-to-revenue ratio is the single number I would watch most closely: if it normalizes below 12% of revenue while growth holds, FCF recovers and the equity story strengthens. If it stays above 18% and growth stays below 8%, the FCF CAGR goes more negative and the "quality compounder" label stops being accurate.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Novo Nordisk is a textbook high-quality pharma franchise: revenue compounded from $21.9B in 2021 to $48.2B in 2025 (roughly 22% CAGR), with gross margins consistently above 81% and operating margins in the 41-44% band. Net income more than doubled to $15.96B and FCF ran at $9-13B annually, with OCF/NI of 1.25x, accruals at -5.8% of assets, Beneish M of -2.58, and Altman Z of 4.13 - all pointing to genuine, cash-backed earnings with no forensic red flags. SBC is a trivial 0.5% of revenue.
Verify before trusting this (5)
- Confirm the 2022-to-2023 share count jump from 2.27B to 4.49B is a stock split, not equity issuance
- Root cause of 2025 margin compression - manufacturing scale-up, pricing pressure, or Wegovy competition from Lilly
- Customer/payer concentration and rebate exposure in US GLP-1 sales
- Capex intensity and manufacturing capacity commitments driving the FCF gap versus net income
- Debt maturity ladder behind the $16.3B net debt position
The composite fair value of $48.24 and signal-adjusted $51.07 bracket the $47.11 price within roughly 2-8% - that is noise, not mispricing. DCF at $53.45 implies ~13% upside, but the EPV floor at $37.83 says if growth flatlines the stock is actually ~20% too expensive. That spread tells you the entire debate is about whether GLP-1 growth persists; today's price roughly splits the difference. The strong-quality lens supports leaning on the higher end of the range, but the 2025 margin inflection (gross -370bps, operating -290bps, FCF -30% from peak) argues against paying above deserved value. Net: the market has this one about right. There is no visible margin of safety, but no obvious excess either. A steady compounder at a fair price - fine to own, not a table-pounding buy. I would want a mid-single-digit to low-teens discount to the composite before calling it attractive, given competitive (Lilly) and reimbursement risk that could compress the DCF toward the EPV floor.
Verify before trusting this (4)
- Q4 and forward guidance on Wegovy/Ozempic pricing net of rebates as US payer pressure builds
- Gross margin trajectory - is the 370bps drop a one-time capacity build or structural
- Competitive share loss to Lilly's tirzepatide/retatrutide in obesity
- Capex and manufacturing spend guidance - impacts FCF and DCF terminal
The macro tape is mildly risk-on, but with beta 0.35 that barely registers for NVO. What actually presses on this name is the narrative: the once-cult GLP-1 story has moderated into a 'steady compounder' frame, and inside that frame NVO is being cast as the loser in the Lilly-vs-Novo split screen. Recent headlines explicitly contrast Lilly raising guidance against Novo's layoffs, pipeline writedowns, and a dramatic price cut — that is a narrative wound specific to this ticker, not a sector one. The late-July ziltivekimab ZEUS failure (-8.8%) also punctured the 'diversification beyond obesity' leg of the bull case. Momentum confirms the pressure: 3-year deceleration, recent 6.4% trailing the 15.4% long-term CAGR. Offsets exist but are smaller in intensity: the CEO is actively pushing back on winner-take-all framing, the Lexicon LX9851 Phase 1 milestone gave a real +3.7% pop, Q2 guidance was raised, and an active buyback provides a bid. Analyst/news tone is genuinely mixed rather than capitulatory, which keeps this a Headwind rather than a Strong Headwind. Net: the story is working against NVO more than for it, but the low beta and defensive sector mute the damage.
Verify before trusting this (5)
- Any incremental U.S. pricing / reimbursement headlines that could deepen the price-cut narrative
- Lilly's next earnings or guidance update — a further gap widens the split-screen headwind
- Wegovy pill uptake data in coming months as a live test of the durable-category thesis
- Follow-through on LX9851 and other oral obesity candidates to rebuild pipeline narrative
- Whether sell-side target revisions turn net negative after the layoffs/writedowns headlines
The world is doing exactly what the bull case wanted — mass-market adoption of GLP-1s — but the economics of that adoption are being rewritten in real time. Payers, governments and cash-pay channels are converting a premium specialty drug into a volume commodity, and a two-supplier market with a clear efficacy leader means the follower absorbs most of the price concession. Macro headwinds (10y at 4.7) matter little to drug demand but raise the bar on capital-intensive capacity builds already showing up in negative FCF. The structural question is not whether obesity treatment grows — it does — but whether Novo captures a stable share of it. Current evidence says its share is drifting down while the pie grows, which converts a hypergrowth story into a mid-single-digit volume-versus-price grind. That is not collapse; it is normalization to something closer to a large-cap pharma with one contested franchise and a 2031 US patent horizon.
When we made this prediction on Aug 27, 2026, NVO was $46.07. We expect it to be $51.00 by Feb 2027, and we consider it great value under $40.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 27, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.
adjusted_earnings
flips up 25%
cost_of_capital
flips down 25%
shares
flips down 25%